This trial is evaluating whether Nivolumab will improve 2 primary outcomes and 4 secondary outcomes in patients with Eye and Orbit. Measurement will happen over the course of Until up to 6 subjects can be adequately assessed for DLT..
This trial requires 20 total participants across 2 different treatment groups
This trial involves 2 different treatments. Nivolumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"For ophthalmic surgeries, nearly all procedures are performed by elective surgery specialists, most frequently by general surgical procedures. Approximately 10,000 eye and orbital surgeries are performed in the United States of America each year. More than 70% of these procedures are performed by general surgical specialists. The number of surgeries performed by ophthalmologists/ orbital surgeons is significantly less than the number performed by optometrists or the number performed by general surgeons." - Anonymous Online Contributor
"Different treatments exist depending on the specific patient and their underlying disease. Treatment is likely to be dependent on the type of tumor and how far it has progressed." - Anonymous Online Contributor
"The current literature provides evidence that eye and orbital surgery is often curative. We do not have sufficient conclusive evidence for evidence-based consensus resolution for eye and orbital surgery to be considered curative." - Anonymous Online Contributor
"Crowding of the eye by the mandible is a major risk factor for eye disease, as seen in trachoma, corneal opacities, and uveitis. Refractive errors could result from refractive surgery, including refractive errors caused by the mandible. Mandibular deviations caused by dental work. Other causes of eye disease include cataracts, glaucoma, retinopathy from diabetes, and uveitis. The main cause of eye and orbit disease (including refractive errors and trauma) is poor nutrition." - Anonymous Online Contributor
"The most common disorder encountered by primary care physicians is eye injury due to violence, followed by trauma to the orbit, periorbital sinus, and ear." - Anonymous Online Contributor
"Anterior uveitis is the leading cause of eye pain and blurred vision. Ocular pain and redness have been suggested as indications of ocular involvement in Graves' thye, but the diagnosis is primarily made on the basis of symptoms and examination findings. Miosis may be a sign of exophthalmos and proptosis or a sign of orbital perforation." - Anonymous Online Contributor
"Nivolumab was associated with a slight increase in the cumulative hazard of SIE in patients with mCRC. This effect was similar regardless of T-Lineage Status and Tumor Suppressor Status." - Anonymous Online Contributor
"The last decade is marked by a substantial number of publications concerning eye and orbital surgery and the development in new diagnostic and therapeutic ophthalmic surgical methods." - Anonymous Online Contributor
"These ADME information can help inform on the prescribing of anti-PD-1 medications in clinical practice. Most of the ADME information on nivolumab showed the drugs as having few adverse effects. Most of the information related to the effects of nivolumab are the same for all antibodies. ADME information for antibodies such as abatacept, ixekizumab, or raxibacumab will also help guide on the patient's treatment." - Anonymous Online Contributor
"The use of nivolumab with any treatment other than gemtuzumab ozogamicin resulted in more toxicities. Patients most likely to qualify for combination therapy are those who have undergone an autologous stem cell transplant and chemotherapy in the past, and are treated with nivolumab. Prospective cohorts of patients who are candidates for combination therapy are urgently needed to prevent unnecessary toxicity of nivolumab combined with chemotherapy." - Anonymous Online Contributor
"Trial investigators should assess whether their work and clinical practice includes patients who may benefit from clinical trials and consider which clinical sites would be appropriate to participate in a trial of interest. They should also evaluate whether local ethics committees and their local regulatory authorities could be appropriate places for trial protocols to be developed and approved." - Anonymous Online Contributor
"The primary cause of eye and orbital disease is [glaucoma] (50%). Other primary causes including hereditary disorders, trauma, intraoperative complications, uveitis, eye infections, [ocular cancer, and other tumours] accounted for another 25%. In some cases, ocular manifestations in one eye may indicate that the condition is on the way to developing in the second eye but it is also possible that it is just the patient exhibiting unilateral symptoms. When the cause is unknown, it is necessary to exclude a [disease process of the eye and its surrounding tissue] since this is also usually the case." - Anonymous Online Contributor